Fig. 3

AAV2/8-mediated gene delivery of APN^C39S transgene to 5xFAD exhibits dose-dependent transduction efficiency, liver-specific expression of transgene and increase of circulatory adiponectin. A AAV plasmids design of control GFP and APN^C39S. B Fluorescence of GFP in the liver and duodenum of AAV2/8-GFP-treated 5xFAD 1 month after injection. (n = 3 mice). C Vector copy number of APN transgene in the liver, duodenum and muscle of AAV2/8-APN^Tri-treated 5xFAD at different doses 1 month after injection. (n = 3 mice for each experimental group). D ELISA analysis of plasma APN in AAV2/8-APN^Tri-treated 5xFAD at different doses 1 month after injection. (n = 6 mice for each experimental group). E Fold change analysis of plasma APN in AAV2/8-APN^Tri-treated 5xFAD at different doses 1 month after injection (normalized by wildtype plasma APN). Data were presented as the mean ± s.e.m. *p < 0.05; **p < 0.01; ***p < 0.001. Statistical analysis was performed by one-way ANOVA followed with Bonferroni’s post hoc comparison tests.